The FDA has reviewed the first module of Implantica AG's application for RefluxStop™, an anti-reflux device.

The FDA has accepted and completed its review of Module 1 of Implantica AG's PMA application for RefluxStop™, a device aimed at treating acid reflux. This module included quality systems and manufacturing details. Before final approval, the FDA will inspect production sites to ensure compliance. RefluxStop™, already CE-marked in Europe, aims to revolutionize anti-reflux treatment options.

5 weeks ago
5 Articles

Further Reading